Actelion To Begin Phase III Bosentan Trial In Second Quarter
Actelion plans to initiate a large Phase III trial of the endothelin receptor antagonist bosentan in congestive heart failure patients during the second quarter of 1999.
Actelion plans to initiate a large Phase III trial of the endothelin receptor antagonist bosentan in congestive heart failure patients during the second quarter of 1999.